TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVALatest QuantConomy context for TEVA: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Teva Pharmaceutical Industries Ltd is an Israeli multinational pharmaceutical company and the world's largest generic drug manufacturer. Founded in 1901, Teva is headquartered in Israel and operates in over 60 countries, with a global workforce of approximately 37,000 employees. The company specializes in developing, producing, and distributing a wide range of pharmaceutical products, including generic drugs, branded drugs such as Austedo and Ajovy, active pharmaceutical ingredients (APIs), and over-the-counter treatments. Teva's product portfolio includes more than 3,600 medicines, and it produces around 76 billion tablets and capsules annually. The company is committed to improving health outcomes by providing affordable, high-quality medications to around 200 million people every day, with a strong focus on core therapeutic areas like movement disorders, migraine, neuropsychiatry, and respiratory conditions. Teva is listed on the Tel Aviv Stock Exchange and the New York Stock Exchange.
- Symbol
- TEVA
- Name
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec nasdaq lse
Recent signals for TEVA
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| volume dry up | neutral | 16 | Jul 10, 05:10 PM | TEVA volume dry-up: 23% of expected volume for Friday 17:00 UTC, price flat 0.03% (strength 16) |
| volume dry up | neutral | 16 | Jul 10, 04:13 PM | TEVA volume dry-up: 23% of expected volume for Friday 16:00 UTC, price flat 0.00% (strength 16) |
| volume major spike | neutral | 85 | Jul 10, 03:38 PM | TEVA major volume spike: 1619% of expected volume for Friday 15:00 UTC, price flat 0.11% (strength 85) |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| TEVA | NYSE | alphavantage | Teva- Pharmaceutical Industries Ltd |
| TEVA | NYSE | fmp | Teva Pharmaceutical Industries Limited |
| TEVA | NYSE | alpaca | Teva Pharmaceutical Industries Limited American Depositary Shares |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Shields Matthew | EVP, Global Operations | sale | 9,989 | $32.19 | $321,547 | 4 on EDGAR |
| Jun 11, 2026 | Kalif Eliyahu Sharon | EVP, Chief Financial Officer | sale | 106,563 | $34.10 | $3,633,308 | 4 on EDGAR |
| Jun 5, 2026 | BARER SOL J | Director | exercise | 21,739 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Francis Richard D | President and CEO | exercise | 13,043 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Nisen Perry | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Elstein Amir | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Lichtenstein Chen | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Satchi-Fainaro Ronit | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Zaks Tal Zvi | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | LIEBERMAN GERALD M | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | Crane Rosemary A | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 5, 2026 | MIGNONE ROBERTO | Director | exercise | 14,492 | — | — | 4 on EDGAR |
| Jun 3, 2026 | Shields Matthew | EVP, Global Operations | exercise | 16,195 | — | — | 4 on EDGAR |
| May 28, 2026 | Nisen Perry | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | Zaks Tal Zvi | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | MIGNONE ROBERTO | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | Elstein Amir | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | Lichtenstein Chen | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | LIEBERMAN GERALD M | Director | grant | 7,242 | — | — | 4 on EDGAR |
| May 28, 2026 | BARER SOL J | Director | grant | 10,863 | — | — | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query TEVA context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access